Enhertu approved in US for breast cancer post ET
28 January 2025
Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following…
94,960$
1,01%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
FDA Expands Label of AZNs Enhertu for New Breast Cancer Indication
The FDA approves AstraZenecas sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer in the United States.…
AstraZenecas Enhertu gets additional FDA approval
…
This Is the Most Promising Quantum Computing Stock, but Should You Buy It Right Now?
Quantum computing has the potential to accelerate how companies and scientists process data, which could lead to more advanced artificial…
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress…